FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report
BackgroundMyasthenia gravis (MG) is an autoimmune neuromuscular disorder in which approximately 10–15% of patients with generalized AChR antibody–positive MG develop refractoriness to standard immunosuppressive therapies. Advanced therapeutic strategie…